Olga Triantafylli

Papers

1

Total Citations

17

H-Index

1

About

Olga Triantafylli is a researcher whose work bridges pharmaceutical analysis and pharmacogenomics, with a focus on personalized medicine. Her key research areas include drug metabolism, pharmacokinetics, and the genetic factors influencing therapeutic outcomes. Her most notable contribution is a 2016 study examining how CYP2C19 polymorphisms affect omeprazole pharmacokinetics, using validated LC–MS/MS and Real Time-PCR methods. This work, which has garnered 17 citations, provides critical insights into how genetic variations can alter drug efficacy and safety, particularly for proton pump inhibitors widely used in gastrointestinal disorders. By integrating advanced analytical chemistry with molecular biology, Triantafylli’s research highlights the importance of tailoring drug dosages based on individual genetic profiles. Her findings have implications for optimizing treatment protocols and reducing adverse drug reactions, making her a valuable contributor to the field of precision pharmacology. For students and researchers, her work exemplifies how combining analytical techniques with genetic analysis can advance our understanding of drug–gene interactions, paving the way for more effective and personalized therapeutic strategies.

Research Focus

Key Achievements

1
H-Index
1
Papers
17
Total Citations
17
Avg Citations/Paper
🏆 Most Cited Paper
Study of the effect of CYP2C19 polymorphisms on omeprazole pharmacokinetics by utilizing validated LC–MS/MS and Real Time-PCR methods
17 citations · 2016
📈 Most Prolific Year: 2016 (1 Papers)
🤝 Key Collaborators: 7

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago